These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20831292)

  • 21. Looking at CER from Medicare's perspective.
    Mohr P
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S5-8. PubMed ID: 22578211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A tall order on a tight timeframe: stakeholder perspectives on comparative effectiveness research using electronic clinical data.
    Holve E; Lopez MH; Scott L; Segal C
    J Comp Eff Res; 2012 Sep; 1(5):441-51. PubMed ID: 24236421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.
    Oderda GM; Balfe LM
    J Manag Care Pharm; 2011; 17(9 Suppl B):S19-24. PubMed ID: 22073936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
    Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
    J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
    Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ARRA investment in CER: a description of the midstream evaluation and how the funds were allocated and CER priorities addressed.
    Esposito D; Yong PL; Rich E; Geonnotti K; Kimmey LD
    J Comp Eff Res; 2014 Nov; 3(6):581-9. PubMed ID: 25494564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of comparative effectiveness research on health and health care spending.
    Basu A; Jena AB; Philipson TJ
    J Health Econ; 2011 Jul; 30(4):695-706. PubMed ID: 21696840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Effectiveness Research: A Roadmap for Physical Activity and Lifestyle.
    Jakicic JM; Sox H; Blair SN; Bensink M; Johnson WG; King AC; Lee IM; Nahum-Shani I; Sallis JF; Sallis RE; Craft L; Whitehead JR; Ainsworth BE
    Med Sci Sports Exerc; 2015 Aug; 47(8):1747-54. PubMed ID: 25426735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Public Spending on Health Service and Policy Research in Canada, the United Kingdom, and the United States: A Modest Proposal.
    Thakkar V; Sullivan T
    Int J Health Policy Manag; 2017 Nov; 6(11):617-620. PubMed ID: 29179288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global comparative healthcare effectiveness research: evaluating sustainable programmes in low & middle resource settings.
    Balkrishnan R; Chang J; Patel I; Yang F; Merajver SD
    Indian J Med Res; 2013 Mar; 137(3):494-501. PubMed ID: 23640555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Looking at CER from the managed care organization perspective.
    Cannon HE
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S13-6. PubMed ID: 22578213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The policy debate over public investment in comparative effectiveness research.
    Rich EC
    J Gen Intern Med; 2009 Jun; 24(6):752-7. PubMed ID: 19381731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating economic evaluation methods into clinical and translational science award consortium comparative effectiveness educational goals.
    Iribarne A; Easterwood R; Russo MJ; Wang YC
    Acad Med; 2011 Jun; 86(6):701-5. PubMed ID: 21512372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating comparative effectiveness research into Medicaid payment policy: views from medical and pharmacy directors.
    Weissman JS; Westrich K; Hargraves JL; Pearson SD; Dubois R; Emond S; Olufajo OA
    J Comp Eff Res; 2015 Mar; 4(2):79-88. PubMed ID: 25825839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementing CER: what will it take?
    Biskupiak JE; Dunn JD; Holtorf AP
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S19-29. PubMed ID: 22663296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy.
    Ahmed S; Berzon RA; Revicki DA; Lenderking WR; Moinpour CM; Basch E; Reeve BB; Wu AW;
    Med Care; 2012 Dec; 50(12):1060-70. PubMed ID: 22922434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons from comparative effectiveness research methods development projects funded under the Recovery Act.
    Zurovac J; Esposito D
    J Comp Eff Res; 2014 Nov; 3(6):601-7. PubMed ID: 25494566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
    Milne CP; Cohen JP; Felix A; Chakravarthy R
    Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.